
CytomX Therapeutics fell 50.1% from $3.77 to $1.88, behind the S&P 500's +9.7%. Its worst day was Mar 18 (−19.3%), and its low came Nov 18 at $1.88.
Nov 20, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
CytomX Therapeutics shares rose 26.8%, while the S&P 500 fell 0.1%.
+26.8% · S&P 500 −0.1%
EPS of $-0.22 missed the $-0.09 estimate on $663,000.00 revenue (est. $7.3M).
+44.2%, the year's best day, on 121M shares, the year's heaviest volume · S&P 500 +1.0%
Story events cover the past 12 months · Times ET
EPS of $-0.10 beat the $-0.12 estimate on $10.3M revenue (est. $4.4M).
−0.5% · S&P 500 +0.8%
EPS of $-0.09 beat the $-0.10 estimate on $1.4M revenue (est. $11.3M).
+2.7% · S&P 500 +0.6%
CytomX Therapeutics shares fell 15.9%, while the S&P 500 fell 0.5%.
−15.9% · S&P 500 −0.5%
EPS of $-0.09 missed the $-0.07 estimate on $1.7M revenue (est. $9.2M).
+2.3% · S&P 500 +0.3%
Where it ended: a close of $1.88 on Nov 18, 2026. Up next: Q4 2026 earnings on Mar 15, 2027 (EPS est. $-0.09, revenue est. $8.9M).
Nothing in the past 12 months.
All CTMX dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CTMX and SPY from Benzinga historical bars. Not investment advice.